Randomised clinical trial: the beneficial effects of <scp>VSL</scp>#3 in obese children with non‐alcoholic steatohepatitis

Abstract

A 4-month supplement of VSL#3 significantly improves NAFLD in children. The VSL#3-dependent GLP-1 increase could be responsible for these beneficial effects. Trial identifier: NCT01650025 (www.clinicaltrial.gov).